One of the benefits of using ctDNA as a biomarker is that it allows tracking of new mutations potentially involved in disease progression and/or drug resistance in metastatic lesions . Such mutations may not be in the COSMIC database because of the difficulty in sampling metastatic lesions. However, it is important to note that our approach is diagnostic, and therefore is not appropriate for the research described in this paragraph.